15 min listen
Current Role of Minimal Residual Disease Assessment in the Management of Multiple Myeloma and Chronic Lymphocytic Leukemia with Drs Shaji Kumar and Ph…
Current Role of Minimal Residual Disease Assessment in the Management of Multiple Myeloma and Chronic Lymphocytic Leukemia with Drs Shaji Kumar and Ph…
ratings:
Length:
77 minutes
Released:
Mar 1, 2021
Format:
Podcast episode
Description
Dr Shaji Kumar from the Mayo Clinic in Rochester, Minnesota, and Dr Philip Thompson from the University of Texas MD Anderson Cancer Center discuss the role of minimal residual disease assessment in the management of multiple myeloma and chronic lymphocytic leukemia.
CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMRD21).
CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMRD21).
Released:
Mar 1, 2021
Format:
Podcast episode
Titles in the series (100)
Dr Michael Pishvaian Comments on the Use of PARP Inhibition in the Management of Pancreatic Cancer: Is it worthwhile to treat pancreatic cancer? Dr Michael Pishvaian from Johns Hopkins University discusses the use of the PARP inhibitor olaparib and other new developments in the disease. by Oncology Today with Dr Neil Love